financetom
Business
financetom
/
Business
/
Cronos Group Fluctuating Between Gains and Losses in Premarket Trade as Its Q2 Loss Widened, Despite Record Revenue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cronos Group Fluctuating Between Gains and Losses in Premarket Trade as Its Q2 Loss Widened, Despite Record Revenue
Aug 8, 2024 5:57 AM

08:31 AM EDT, 08/08/2024 (MT Newswires) -- Cronos Group ( CRON ) was fluctuating between gains and losses in premarket Nasdaq trading after the cannabis producer said its second-quarter loss widened despite record revenue.

The company said it lost US$8.76 million from continuing operations in the period, compared with a year-prior loss of US$5.66 million. Net loss and net loss attributable to Cronos Group ( CRON ) were slightly higher than a year earlier, but comprehensive loss was more than double.

Basic and diluted total loss per share of $0.02 was unchanged

Revenue rose 46% to US$27.76 million from US$19.02 million.

"Cronos ( CRON ) achieved its highest quarterly net revenue on record in Q2 2024 at $27.8 million, up 46% year-over-year. The top line was propelled by 46% growth year-over-year in Canada, 27% growth year-over-year in Israel, growth in Germany and the initiation of sales in the United Kingdom," chief executive Mike Gorenstein said in a release.

The company continues to expect to realize expense reductions of between US$5 million and US$10 million this year but noted it no longer expects to end the year with a higher cash balance as it expands its Cronos Growing unit. It reported a cash position of US$848.19 million in the quarter, more than double the US$409.43 million held in the year-prior quarter.

"Due to the additional $51 million investment in Cronos GrowCo and resulting facility expansion, we no longer anticipate that our net change in cash, defined as the sum of cash and cash equivalents and short-term investments will be positive in 2024," the company said.

Cronos ( CRON ) shares were last seen up US$0.08 to US$2.30 in premarket trading, but they have also dipped lower. They closed down $0.01 to $3.06 Wednesday on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved